By KIM BELLARD Everything’s about AI these days. Everything is going to be about AI for a while. Everyone’s talking about it, and most of them know more about it than I do. But there is one thing about AI that I don’t think is getting enough attention. I’m old enough that the mantra “follow…
Fello’s $10.4 million raise includes a seed investment from Glen Tullman’s 62Ventures, The Capital Factory Fellowship Fund, Katalyst Capital and Offline Ventures. The post Peer Support Platform Fello Secures $10.4M To Combat Loneliness Epidemic appeared first on MedCity News.
Don’t wait—time is running out! The December 15 deadline to apply, renew, or make changes for Marketplace coverage starting January 1 is fast approaching. Take action now to ensure you don’t experience any gaps in your coverage. Image Prioritize your health in 2025: Apply today Kick off 2025 by getting health coverage for you and…
The answer is ‘yes’, but the question is in what manner? A paper by Che et al. (2024) examines the use of real-world data (RWD) across 2016-2023 HTA assessments. Over this time period, 11% of HTA submissions included real-world data. Further, they find that: The main sources of RWD considered in the submissions were disease…
The Glp-1 battle heats with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk’s Wegovy. The post Video: Battle of the Bulge – Wegovy vs. Zepbound appeared first on MedCity News.
It’s been a tumultuous past couple years for retail health companies —but there are still reasons to believe in the convenient model that retail health offers, said Annie Lamont, managing partner and co-founder of Oak HC/FT. The post Why One Investor Still Believes in Retail Health appeared first on MedCity News.
Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications. The post Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head…
In response to emailed questions, the founders of MucoLife Therapeutics shared their company’s approach, which is designed to help people with COPD, cystic fibrosis, asthma, and pulmonary fibrosis. The post A Biotech Startup’s Quest to Relieve Pulmonary Mucus Obstruction for Respiratory Care appeared first on MedCity News.
Focusing on comprehensive strategies and embracing flexible technology solutions arms pharmacy leaders to stay ahead of industry changes, connect teams, and integrate information efficiently. The post 10 Imperatives of a Medication Intelligence System to Streamline the Pharmacy Lifecycle appeared first on MedCity News.
It comes down to two simple questions that every health plan should consider: “Are we a company that pays for services and manages risks? Or are we a company that delivers better health for our members?” The post Healthcare’s Next Frontier: Building a Fully Connected Experience appeared first on MedCity News.